Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH) branch BYS30 particles obtained the drug clinical trial approval notice.

Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH) announced that its subsidiary Guangzhou Baiyunshan Pharmaceutical Holdings Pharmaceutical Group Co., Ltd. has received the approval notice for clinical trials of a drug named BYS30 Granule from the National Medical Products Administration. In accordance with the Drug Administration Law of the People's Republic of China and relevant regulations, the clinical trial application for BYS30 Granule (CXZL2400072) submitted on October 29, 2024, has been reviewed and found to meet the requirements for drug registration. After further refinement of the clinical trial plan, the drug is approved for clinical trials for the treatment of knee osteoarthritis.